Browse MED12

Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF09497 Transcription mediator complex subunit Med12
PF12145 Eukaryotic Mediator 12 subunit domain
PF12144 Eukaryotic Mediator 12 catenin-binding domain
Function

Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. This subunit may specifically regulate transcription of targets of the Wnt signaling pathway and SHH signaling pathway.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001756 somitogenesis
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0003002 regionalization
GO:0003401 axis elongation
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0007164 establishment of tissue polarity
GO:0007389 pattern specification process
GO:0007422 peripheral nervous system development
GO:0007492 endoderm development
GO:0007507 heart development
GO:0009755 hormone-mediated signaling pathway
GO:0009952 anterior/posterior pattern specification
GO:0010001 glial cell differentiation
GO:0014003 oligodendrocyte development
GO:0014020 primary neural tube formation
GO:0014037 Schwann cell differentiation
GO:0014044 Schwann cell development
GO:0016055 Wnt signaling pathway
GO:0016331 morphogenesis of embryonic epithelium
GO:0019827 stem cell population maintenance
GO:0021510 spinal cord development
GO:0021782 glial cell development
GO:0021915 neural tube development
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030521 androgen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035282 segmentation
GO:0035567 non-canonical Wnt signaling pathway
GO:0036342 post-anal tail morphogenesis
GO:0042063 gliogenesis
GO:0043401 steroid hormone mediated signaling pathway
GO:0048545 response to steroid hormone
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048702 embryonic neurocranium morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048709 oligodendrocyte differentiation
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0061053 somite development
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0072175 epithelial tube formation
GO:0090175 regulation of establishment of planar polarity
GO:0090245 axis elongation involved in somitogenesis
GO:0098727 maintenance of cell number
GO:0198738 cell-cell signaling by wnt
GO:1904888 cranial skeletal system development
GO:1905330 regulation of morphogenesis of an epithelium
GO:1990403 embryonic brain development
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001104 RNA polymerase II transcription cofactor activity
GO:0001105 RNA polymerase II transcription coactivator activity
GO:0001158 enhancer sequence-specific DNA binding
GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding
GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding
GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
GO:0004842 ubiquitin-protein transferase activity
GO:0008013 beta-catenin binding
GO:0008022 protein C-terminus binding
GO:0008134 transcription factor binding
GO:0019787 ubiquitin-like protein transferase activity
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity
GO:0035257 nuclear hormone receptor binding
GO:0035326 enhancer binding
GO:0042809 vitamin D receptor binding
GO:0046966 thyroid hormone receptor binding
GO:0051427 hormone receptor binding
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0005813 centrosome
GO:0016592 mediator complex
> KEGG and Reactome Pathway
 
KEGG hsa04919 Thyroid hormone signaling pathway
Reactome R-HSA-1266738: Developmental Biology
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MED12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MED12 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MED12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3170.177
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4330.769
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2320.834
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.350.303
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1830.942
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5680.866
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2440.473
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1740.913
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3470.843
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8290.505
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4410.398
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0910.0571
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MED12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MED12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MED12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MED12.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MED12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MED12 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MED12 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMED12
Namemediator complex subunit 12
Aliases CAGH45; HOPA; TRAP230; KIAA0192; OKS; TNRC11; FGS1; trinucleotide repeat containing 11 (THR-associated prote ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MED12 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.